Pharmacy resident participation with a 24-hour multidisciplinary stroke response team

Pandya, Komal A.; Ruf, Kathryn M.; Winstead, P. Shane; Cook, Aaron M.; Weant, Kyle A.
November 2010
American Journal of Health-System Pharmacy;11/15/2010, Vol. 67 Issue 22, p1901
Academic Journal
The article reports on the use of alteplase, a recombinant tissue plasminogen activator approved by the U.S. Food and Drug Administration, to restrict damage to ischemic stroke patients. It mentions several complications of the therapy which include the bleeding risk, the required intense patient monitoring, and the possibility for major medication errors. Furthermore, the roles of protocol enhancement as well as pharmacy involvement for multidisciplinary stroke response teams are discussed.


Related Articles

  • TPA (Altepase) for Acute Ischemic Stroke.  // ED Nursing;Jan2011 Supplement, p1 

    The article offers guidelines on how to administer Tissue Plasminogen Activator (TPA) to an adult suffering from acute ischemic stroke in the U.S. It states that patient and family must be informed about the intracerebral hemorrhage risk of thrombolytic therapy and must be written on the consent...

  • Standard of Care for tPA for Stroke Has Evolved.  // ED Legal Letter;Nov2010, Vol. 21 Issue 11, p129 

    The article describes the evolution of standard of care for tissue plasminogen activator (tPA) for stroke patients. It reveals that the use of tPA in eligible patients had become a public expectation. The article also highlights the views of various emergency medical physicians on the standard...

  • Investigation of the causes of clinical symptom aggravation in process of intravenous thrombolysis with alteplase. ZHANG Chen-hao; ZHANG Pei-lan; CHEN Yan; LI Chen-hua; WANG Yu-xin // Chinese Journal of Contemporary Neurology & Neurosurgery;Apr2013, Vol. 13 Issue 4, p297 

    Objective To explore the causes of aggravation of microcirculation disorders in the process of intravenous thrombolysis with alteplase and the clinical outcomes. Methods The clinical data of the aggravated signs and symptoms of 13 cases treated by alteplase were reported, and the onset...

  • Lessons learned from a pharmacy practice model change at an academic medical center. Knoer, Scott J.; Pastor III, John D.; Phelps, Pamela K. // American Journal of Health-System Pharmacy;11/1/2010, Vol. 67 Issue 21, p1862 

    Purpose. The development and implementation of a new pharmacy practice model at an academic medical center are described. Summary. Before the model change, decentralized pharmacists responsible for order entry and verification and clinical specialists were both present on the care units. Staff...

  • Impact of health information technology on detection of potential adverse drug events at the ordering stage. Roberts, Lance L.; Ward, Marcia M.; Brokel, Jane M.; Wakefield, Douglas S.; Crandall, Donald K.; Conlon, Paul // American Journal of Health-System Pharmacy;11/1/2010, Vol. 67 Issue 21, p1838 

    Purpose. The impact of implementing commercially available health care information technologies at hospitals in a large health system on the identification of potential adverse drug events (ADEs) at the medication ordering stage was studied. Methods. All hospitals in the health system had...

  • Hyper-acute stroke treatment: the first 48 hours. Nazarko, Linda // British Journal of Healthcare Assistants;Oct2013, Vol. 7 Issue 10, p486 

    Every year, 150 000 people in the UK suffer a stroke. This works out at one every five minutes (Townsend et al, 2012). Stroke is the single largest cause of disability and the third largest cause of deaths in England. Stroke costs the NHS over £2.8 billion and can lead to death or severe...

  • Review questions success of 170m depression programme. White, Daniel // Independent Nurse;9/6/2010, p7 

    The article reports that a review of the Improving Access Psychological Therapies (IPAT) programme in Great Britain found that many unsuitable patients are in the program.

  • Neuro Involved in tPA Decision?  // ED Legal Letter;Nov2010, Vol. 21 Issue 11, p130 

    The article discusses the role of neurologists in the administration of tissue plasminogen activator (tPA) in stroke patients. It cites the significance of neurologists when providing immediate care and evaluation to stroke patients. It offers ideas on what actions should be taken if a...

  • Ask the Experts. Use of Tissue Plasminogen Activator to Treat Acute Ischemic Stroke. Alexandrov, Anne W. // Critical Care Nurse;Oct2010, Vol. 30 Issue 5, p77 

    The article provides an answer to a question on the use of tissue plasminogen activator to treat acute ischemic stroke.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics